Anúncio
Anúncio

URGN

URGN logo

UroGen Pharma Ltd. Ordinary Shares

21.25
USD
Patrocinado
-2.24
-9.54%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pré-Mercado

21.33

+0.08
+0.38%

Relatórios de Lucros URGN

Rácio de surpresa positiva

URGN separação 16 de 34 últimas estimativas.

47%

Próximo Relatório

Data do Próximo Relatório
09 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$42.28M
/
-$0.49
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+53.84%
/
-28.99%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+72.11%
/
-38.75%

UroGen Pharma Ltd. Ordinary Shares earnings per share and revenue

On 06 de nov. de 2025, URGN reported earnings of -0.69 USD per share (EPS) for Q3 25, beating the estimate of -0.70 USD, resulting in a 2.32% surprise. Revenue reached 27.48 milhão, compared to an expected 33.76 milhão, with a -18.58% difference. The market reacted with a +21.91% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.49 USD, with revenue projected to reach 42.28 milhão USD, implying an diminuir of -28.99% EPS, and aumentar of 53.84% in Revenue from the last quarter.
FAQ
For Q3 2025, UroGen Pharma Ltd. Ordinary Shares reported EPS of -$0.69, beating estimates by 2.32%, and revenue of $27.48M, -18.58% below expectations.
The stock price moved up 21.91%, changed from $19.31 before the earnings release to $23.54 the day after.
The next earning report is scheduled for 09 de mar. de 2026.
Based on 10 analistas, UroGen Pharma Ltd. Ordinary Shares is expected to report EPS of -$0.49 and revenue of $42.28M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio